Juniper Pharmaceuticals, Inc. (JNP) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) have received an average recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $12.00.

Several equities analysts have recently issued reports on JNP shares. TheStreet upgraded shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a report on Wednesday, April 12th. HC Wainwright restated a “hold” rating on shares of Juniper Pharmaceuticals in a report on Friday, May 5th. Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 6th. Finally, ValuEngine downgraded shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd.

Juniper Pharmaceuticals (NASDAQ:JNP) traded down 6.31% during mid-day trading on Friday, reaching $5.20. 28,845 shares of the company’s stock were exchanged. The firm has a market capitalization of $56.38 million, a P/E ratio of 9.20 and a beta of 0.30. The company’s 50-day moving average is $4.49 and its 200 day moving average is $4.82. Juniper Pharmaceuticals has a one year low of $3.65 and a one year high of $8.00.

Juniper Pharmaceuticals (NASDAQ:JNP) last announced its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.04. Juniper Pharmaceuticals had a return on equity of 19.03% and a net margin of 12.00%. The firm had revenue of $11.25 million during the quarter, compared to the consensus estimate of $11.27 million. Equities analysts predict that Juniper Pharmaceuticals will post ($0.45) earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Juniper Pharmaceuticals by 7.6% in the fourth quarter. Renaissance Technologies LLC now owns 254,300 shares of the specialty pharmaceutical company’s stock valued at $1,424,000 after buying an additional 17,900 shares during the period. Acadian Asset Management LLC increased its position in Juniper Pharmaceuticals by 6.6% in the first quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,544 shares during the period. Algert Global LLC increased its position in Juniper Pharmaceuticals by 28.9% in the first quarter. Algert Global LLC now owns 108,315 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 24,270 shares during the period. TFS Capital LLC increased its position in Juniper Pharmaceuticals by 87.0% in the first quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 14,707 shares during the period. Finally, Vanguard Group Inc. increased its position in Juniper Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 451,338 shares of the specialty pharmaceutical company’s stock valued at $2,144,000 after buying an additional 1,942 shares during the period. Hedge funds and other institutional investors own 34.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Juniper Pharmaceuticals, Inc. (JNP) Given Consensus Recommendation of “Hold” by Brokerages” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/06/23/juniper-pharmaceuticals-inc-jnp-given-consensus-recommendation-of-hold-by-brokerages.html.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc, formerly Columbia Laboratories, Inc, is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE.

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply